Under the radar Bellicum has turned a Car-t into a solid tumor killer contender. Today's clinical abstract is fantastic. http://ir.bellicum.com/phoenix.zhtml?c=253830&p=irol-newsArticle&ID=2054576 http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTUxOTUxOTB8Q2hpbGRJRD01ODI3NDU= Their pipeline is robust, with blood (t cell depleted), dendritic cells and Car-T on/off switch technologies. http://ir.bellicum.com/phoenix.zhtml?c=253830&ut=1433006193&p=RssLanding&cat=news&id=2048147 I'm expecting the market to take notice soon. :)